You are here

Articles

Posted on Saturday, December 6, 2014 - 1:57pm
This article is a retrospective, single-institution review of the incidence and clinical characteristics of late chronic anemia associated with prolonged use of imatinib for patients with chronic myeloid leukemia. The...
Posted on Saturday, October 25, 2014 - 1:57pm
24/10/2014 European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig The European Medicines Agency (EMA) has concluded its review of the benefits and risks of Iclusig (...
Posted on Tuesday, October 7, 2014 - 1:13pm
Treatment Recommendations for People Living with CML
Posted on Monday, October 6, 2014 - 5:17pm
This is a summary of the European public assessment report (EPAR) for Imatinib Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of...
Posted on Thursday, September 25, 2014 - 12:22pm
Timothy Hughes and Deborah White.
Posted on Sunday, September 14, 2014 - 4:18pm
10 Mar 2014 Researchers in Manchester have investigated the stickiness of leukaemia cells, and whether this is linked to drug resistance.
Posted on Sunday, September 14, 2014 - 4:10pm
News | September 03, 2014 | Leukemia & Lymphoma, Chronic Myeloid Leukemia, Hematologic Malignancies By Dave Levitan STAT3 inhibition using a novel compound restored sensitivity to tyrosine kinase inhibitors (TKIs)...
Posted on Saturday, August 9, 2014 - 7:18pm
L Schafranek1,2,3, E Nievergall1,2,3, J A Powell4,5, D K Hiwase3,6, T Leclercq1,3, T P Hughes1,2,3,6,7 and D L White1,2,3,4 Kinase inhibitors block proliferative signals in BCR-ABL1+ leukemic cells, but their capacity...
Posted on Tuesday, August 5, 2014 - 7:44pm
Carlo Gambacorti-Passerini1,*, Jorge E. Cortes2, Jeff H. Lipton3, Anna Dmoszynska4, Raymond S. Wong5, Victor Rossiev6, Dmitri Pavlov7, Karin Gogat Marchant8, Ladan Duvillié8, Navin Khattry9, Hagop M. Kantarjian2 andTim...
Posted on Friday, July 25, 2014 - 7:25pm
Megan Brooks July 25, 2014 With the rapid and widespread uptake of tyrosine kinase inhibitors (TKIs) in oncology over the past several years, serious drug–drug interactions are an "increasing risk," according a new...
Posted on Friday, July 25, 2014 - 7:23pm
Amina Haouala1, Nicolas Widmer1, Michel A. Duchosal2, Michael Montemurro3, Thierry Buclin1, and Laurent A. Decosterd1
Posted on Thursday, July 10, 2014 - 2:17pm
Ghalaut VS1, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R.
Posted on Thursday, July 10, 2014 - 1:14pm
M Agrawal1, B Hanfstein1, P Erben1, D Wolf2, T Ernst3, A Fabarius1, S Saussele1, D Purkayastha4, R C Woodman4, W-K Hofmann1, R Hehlmann1, A Hochhaus3 and M C Müller1 Nilotinib was able to impede proliferation of MDR1-...
Posted on Tuesday, July 8, 2014 - 1:41pm
Timothy P. Hughes1,*, Jeffrey H. Lipton2, Nelson Spector3, Francisco Cervantes4, Ricardo Pasquini5, Nelma Cristina D. Clementino6, Pedro Enrique Dorlhiac Llacer7, Anthony P. Schwarer8, Francois-Xavier Mahon9, Delphine...